RESULTS: GLP-1 receptor agonists have become widely used to treat obesity. Obesity is a known risk factor for the development of IIH, though the precise pathophysiology is unclear. GLP-1 receptor agonists may help treat IIH by promoting weight loss, lipolysis of adipose tissue, and potentially decreasing the secretion of CSF, as was seen in rat models. Abrupt cessation of GLP-1 receptor agonists can result in regaining lost weight rapidly. In the case that we present, the patient stopped duraglutide abruptly due to lack of insurance coverage and regained the weight she had lost within a month. She subsequently developed IIH. GLP-1 receptor agonists have the potential to help treat IIH; however, this class of medication needs to be used carefully, as cessation of the medication and resultant rapid weight gain can result in IIH.
结果:GLP-1受体激动剂已广泛用于治疗肥胖症。肥胖是IIH发展的已知危险因素,尽管确切的病理生理学尚不清楚。GLP-1受体激动剂可能通过促进体重减轻来帮助治疗IIH,脂肪组织的脂解,并可能减少脑脊液的分泌,正如在大鼠模型中看到的那样。突然停止GLP-1受体激动剂可导致快速恢复体重减轻。在我们介绍的情况下,由于缺乏保险,患者突然停止了杜拉鲁肽,并在一个月内恢复了体重减轻。她随后发展了IIH。GLP-1受体激动剂有可能帮助治疗IIH;然而,这类药物需要小心使用,停止药物治疗并导致体重快速增加可能导致IIH。